We’re excited to share that BigHat Biosciences was featured in Gen Edge News. Our co-founder and CSO, Peyton Greenside, discussed how AI is advancing traditional antibody engineering by leveraging diverse antibody sequences, modeling multiple properties simultaneously, and generating novel antibodies to meet unmet medical needs. 

To read full article: https://www.genengnews.com/topics/artificial-intelligence/antibody-discovery-taps-ai-for-multidimensional-optimization/